News from the healthcare data industry
June 23, 2022 Automated system will mean faster results, fewer delays and improved patient outcomes The Tiger Institute for Health Innovation, which provides the technology for University of Missouri Health Care’s...
June 09, 2022 01:03 ET | Source: F. Hoffmann-La Roche Ltd FoundationOne CDx can now be used to identify patients with ROS1 fusion-positive non-small cell lung cancer or patients with NTRK fusion-positive solid tumours for whom...
Initial Goal of Collaboration is to Develop FoundationOne®Liquid CDx as a Companion Diagnostic for Bavdegalutamide (ARV-110), Arvinas’ Investigational Androgen Receptor-Targeting PROTAC® Protein Degrader June 05, 2022 08:05 AM Eastern Daylight...
LEADER Trial Will Use Results from Foundation Medicine’s Comprehensive Genomic Profiling Tests to Screen for Actionable Driver Mutations to Inform Trial Enrollment and Targeted Therapy Options for Patients New “Trial...
Key data reinforce the utility of Foundation Medicine’s tissue- and blood-based comprehensive genomic profiling to support treatment planning, and demonstrate the value of real-world genomic data to facilitate equitable research...
People with different ancestries inherit different risks and encounter different environmental exposures resulting in different somatic profiles. Research Presented at the American Association for Cancer Research (AACR) Annual Meeting, held...
April 13, 2022 09:50 AM Eastern Daylight Time DALLAS–(BUSINESS WIRE)–Texas Oncology announced today that it has entered into an agreement with Foundation Medicine, a pioneer in molecular profiling for cancer,...
New studies demonstrate the ability of Foundation Medicine’s portfolio of tests to improve treatment options for patients, and reinforce the company’s role as an essential partner to researchers April 05,...
Foundation Medicine’s tissue-based test is the first and only comprehensive genomic profiling test to be approved as a companion diagnostic for a third group of targeted therapies March 17, 2022...